Work

Efficacy of fadraciclib (CYC065), a novel dual CDK2/9 inhibitor, on patient-derived models of colorectal cancer.

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.16_suppl.3596

Authors: Mohammad Zokaasadi, Erdem Altunel, Divya Lakshmi Dayanidhi, John B Mantyh, Wylie K Watlington, Shannon J. McCall, David Blake, Jason A. Somarelli, David S. Hsu

Institutions: Duke Medical Center, University of Massachusetts Chan Medical School, Duke University, Cyclacel Pharmaceuticals (United Kingdom)

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4399736935

Cites:

Cited by: 1

Related to: 10